– Bracco announces long-term strategic partnership with ulrich medical for syringeless MRI injectors
The private label deal will bring a new syringeless magnetic resonance (MR) injector to the United States. 510(k) premarket notification has been submitted to the US Food and Drug Administration
MILAN, Italy , Nov. 23, 2023 /PRNewswire/ — Bracco, the global leader in image diagnostics, and ulrich GmbH
Differentiation of organs and tissues is usually only possible with the use of contrast media in medical imaging. Ulrich medical has been offering contrast media injectors for use in computed tomography and magnetic resonance imaging for over 30 years. The injector presented to the FDA is already approved by the European Medicines Agency and is marketed by Ulrich Medical in the European Union and in many other countries around the world.
“Through our strategic collaboration and this private label agreement with ulrich medical, Bracco will bring syringeless MR injectors to the United States and today’s submission for 510(k) clearance to the FDA brings us one step closer to raising the standard of diagnostic imaging solutions worldwide to expand Bracco’s MR portfolio in the United States,” said Fulvio Renoldi Bracco, Vice President and CEO of Bracco Imaging S.p.A. “We are taking bold steps to help make a difference for patients, and this long-term partnership serves as a testament to our commitment to improving the quality and efficiency of healthcare providers.”
“This strategic collaboration with Bracco Imaging to introduce this contrast media injector to the US market represents our commitment to innovation and excellence in healthcare,” said Klaus Kiesel, CEO of ulrich medical. “Together, we hope to set the new standard for patient care in MRI.”
About Bracco ImagingBracco Imaging S.p.A. (“Bracco Imaging”), part of the Bracco Group, is a global innovative leader delivering end-to-end products and solutions through its comprehensive portfolio in diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging’s goal is to improve people’s lives by shaping the future of prevention and precision imaging. Bracco Imaging’s portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), contrast-enhanced ultrasound (CEUS), and nuclear medicine through radioactive tracers and novel agents. of PET images. Bracco Imaging has approximately 3,700 employees and operates in more than 100 markets globally. Bracco Imaging has an innovative and well-trained Research and Development (R&D) organization with an efficient process-oriented approach and a track record in the diagnostic imaging industry. R&D activities are located in four centers based in Italy, Switzerland, the United Kingdom and the United States. Bracco Group’s global revenue was €1.7 billion in 2020. For more information about Bracco Imaging, visit www.bracco.com.
Media contacts
Bracco ImagingMicaela ColamasiSenior Director of HR Communication PP 39 340 9775099Micaela.colamasi@bracco.com
Logo – https://mma.prnewswire.com/media/2157789…
View original content: https://www.prnewswire.com/news-releases/bracco-anuncia-una-asociacion-con-ulrich-medical-para-inyectores-de-resonancia-magnetica-sin-jeringa-301996864.html
